InvestSMART

Immuron Limited (ASX: IMC) - Share Price

- Current share price for IMC : $0.030

Immuron Limited (IMC), an ASX-listed company, is an Australian biopharmaceutical company engaged in the development and commercialization of orally delivered targeted polyclonal antibodies for the treatment of inflammation-related diseases and infectious diseases.

IMC General Information +

ASX Code IMC
Website http://www.immuron.com.au
Industry/Sector Biotechnology
Market Cap ($M) 9
IMC Share Price $0.030
Day High $0.032
Day Low $0.030
Last Close $0.030
IMC Share Price Movement - ( No change )
Prices as at 16:40, 19 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Immuron Limited (IMC) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Immuron Limited (IMC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Immuron Limited (IMC) price-sensitive announcements

IMC - Response to ASX Price Query
Immuron Limited (IMC) responded to a price query from the ASX, confirming that they are un
Immuron Limited (IMC)
28 May 2026 | 12:57 PM
IMC - Immuron Double Digit 3Q Sales Growth
Immuron Limited, an Australian biopharmaceutical company, reported a 16% increase in globa
Immuron Limited (IMC)
17 Apr 2026 | 9:30 AM
IMC - Strategic Update and HY26 Results
Immuron Limited, a commercial-stage biopharmaceutical company, reported its HY26 results a
Immuron Limited (IMC)
25 Feb 2026 | 4:42 PM
IMC - Appendix 4D and Half Year Report
Immuron Limited's Half Year Report for the period ending 31 December 2025 details a compre
Immuron Limited (IMC)
25 Feb 2026 | 3:49 PM

Immuron Limited (IMC) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Immuron Limited (IMC)
ORDINARY FULLY PAID
 Health Care $10 Notification of cessation of securities - IMC 18 Jun 2026 9:55AM $0.033 $0.030 fallen by 9.09%
Immuron Limited (IMC)
ORDINARY FULLY PAID
 Health Care $10 Change in substantial holding 3 Jun 2026 8:19AM $0.046 $0.030 fallen by 34.78%
Immuron Limited (IMC)
ORDINARY FULLY PAID
 Health Care $10 Response to ASX Price Query 28 May 2026 12:57PM $0.041 $0.030 fallen by 26.83%
Immuron Limited (IMC)
ORDINARY FULLY PAID
 Health Care $10 Emerging Growth Conference 8 May 2026 9:27AM $0.026 $0.030 risen by 15.38%
Immuron Limited (IMC)
ORDINARY FULLY PAID
 Health Care $10 Emerging Growth Conference 30 Apr 2026 9:22AM $0.029 $0.030 risen by 3.45%
Immuron Limited (IMC)
ORDINARY FULLY PAID
 Health Care $10 Immuron Double Digit 3Q Sales Growth 17 Apr 2026 9:30AM $0.029 $0.030 risen by 3.45%

IMC Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$5.22 -$2.30 -10.70% 0.00 0.00 0.00% 0.0%
2024A -$5.77 -$2.50 52.40% 0.00 0.00 0.00% 0.0%
2023A -$3.79 -$1.70 32.80% 0.00 0.00 0.00% 0.0%

IMC Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
CSL Limited (CSL) $51,761M 0.1108 -0.1331 0.0165 11.5895 13.3683 13.1510 4.12% 3.32% 3.45%
Clinuvel Pharmaceuticals Limited (CUV) $501M 0.0287 0.0233 0.0942 13.8301 13.5157 12.3523 0.50% 0.73% 1.18%
Immuron Limited (IMC) $11M -0.1067 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast Limited (MSB) $2,667M 0.0301 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,860M -1.3893 0.0000 -0.1292 0.0000 268.1648 307.9570 0.00% 0.00% 0.00%

IMC Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 0.87 0.00
Market 0.29 13.20 1.17 0.67
Sector 0.43 26.00 2.55 2.41

IMC Directors

Name Position Start Date
Mr Daniel Pollock Non-Executive Director 11 Oct 2012
Mr Ravi Savarirayan Non-Executive Director 7 Apr 2017
Dr Jeannie(Jeannette) Joughin Non-Executive Director 1 Jun 2024
Mr Paul Brennan Non-Executive Director, Non-Executive Chairman 16 Mar 2022

Immuron Limited (IMC) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
12 Mar 2024 POLLOCK, Daniel Buy Direct Shares 200,000 $0.120 $24,000.000
12 Mar 2024 POLLOCK, Daniel Exercise Options 200,000 $0.120 $24,000.000
8 Mar 2024 POLLOCK, Daniel Sell Direct Shares 200,000 $0.157 $31,400.000

See all changes in directors' interest & trades for Immuron Limited (IMC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IMC Management

Name Position
Jerry Kanellos Chief Scientific Officer
Flavio Palumbo Chief Commercial Officer
Steven Lydeamore Chief Executive Officer
Olga Smejkalova Company Secretary

IMC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Immuron Limited (IMC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
113,417,824 (42.29%) HSBC Custody Nominees (Australia) Limited

IMC Calendar of Events

Date Event
24 February 2027 Report (Interim)
24 September 2026 Report (Annual)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.